BioSpace News Archive

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced results from a preclinical study evaluating a self-amplifying mRNA (samRNA) vaccine candidate against SARS-CoV-2.

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma.

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new clinical pharmacology data at the Endocrine Society (ENDO) 2022 Annual Conference on its candidate, SPI-62, an HSD-1 inhibitor.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new preclinical data demonstrating the enhanced anti-tumor properties of WU-NK-101, Wugen’s lead memory natural killer (NK) cell therapy product.

Zoetis to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference.

CANbridge Pharmaceuticals Inc. announced that results from its CAN106 Phase 1 trial were presented at the 2022 European Hematology Association Congress, in Vienna, Austria, on June 10th.

Fact.MR, a Market Research and Competitive Intelligence Provider - The global medical nonwoven disposables market is predicted to witness a moderate growth rate of 3.5% during the forecast years 2022 to 2032.

AbbVie announced five-year follow-up results from the Phase 3 CLL14 trial, finding that over 60 percent of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of VENCLYXTO®/VENCLEXTA® plus obinutuzumab continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.

Wilmington, Delaware, United States: According to the report, the global geriatric care services market was valued at US$ 0.4 Bn in 2020.

Wilmington, Delaware, United States: According to the report, the global coronary stents market was valued at US$ 10.1 Bn in 2020 and is projected to expand at a CAGR of 12.9% from 2021 to 2028.